Multiple Complications Secondary to L-asparaginase In a Child with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia: Case Report with Review of Literature

Shyam Srinivasan1, Vikramjit Kanwar1, Soumitra Saha2, Raghavendra Gulabrao Mali3, Tanveer Ahmed Shaikh1, Renu Yadav1, Anubha Jain1

1 Department of Pediatric Oncology, Homi Bhabha Cancer Hospital, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India
2 Department of Pediatric Surgery, Homi Bhabha Cancer Hospital, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India
3 Department of Radiodiagnosis, Homi Bhabha Cancer Hospital, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India

Address for correspondence Shyam Srinivasan, DM, Department of Pediatric Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh 221010, India (e-mail: srinivas.shyam@gmail.com).


Abstract

Keywords
► Philadelphia-chromosome-positive acute lymphoblastic leukemia
► acute pancreatitis
► ventricular thrombus
► gastric perforation
► L-asparaginase

Even though L-asparaginase remains an essential drug for the treatment of childhood acute lymphoblastic leukemia (ALL), its use is associated with several unique toxicities. In this case report, we discuss a young boy with ALL who developed multiple complications simultaneously, including pancreatitis, gastrointestinal perforation, and left ventricular thrombus secondary to L-asparaginase during induction chemotherapy. Patient received immediate surgical intervention for the perforation and was commenced on anticoagulation therapy for the thrombus but eventually expired. This report highlights the importance of being aware of toxicities secondary to the use of L-asparaginase. Multiple complications secondary to L-asparaginase have been rarely reported previously and can be fatal.

Introduction

L-asparaginase has become an integral part in the management of childhood acute lymphoblastic leukemia (ALL) and failure to receive its intended course has been associated with poor outcome.1,2 However, L-asparaginase is also associated with a number of unique toxicities, some of which can have life threatening consequences.3 Here we present a patient with Philadelphia-Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) who experienced two rare complications during induction therapy: gastric perforation and a left ventricular thrombus which led to his demise.

Case Report

An 8-year-old male presented with on and off fever, bruising over shin and chest and easy fatigability for 2 weeks. A complete blood count showed a total leukocyte count (TLC) of 153 × 10⁹/L with a differential count of 60% lymphocytes, 3% neutrophils, 0.1% eosinophils, and 27% blasts in the peripheral blood. A bone marrow examination was done, flow cytometric
analysis along with FISH study which was positive for t(9;22), confirmed the diagnosis of B-lineage Ph⁺ ALL. A real-time quantitative polymerase chain reaction (RT-PCR) was suggestive of p190 BCR/ABL fusion transcript. Cerebrospinal fluid analysis was uninvolved for disease. He was treated as per the modified COG AALL1131 protocol. Induction chemotherapy consisted of prednisolone (60 mg/m²/day; 1–28 days), vincristine (1.5 mg/m²/d; days 1, 8, 15, and 22), native Escherichia coli L-asparaginase (10,000 U/m²/d; days 1, 4, 7, 10, 13, 16, 19, and 22) daunorubicin (30 mg/m²/d; days 1 and 15), intrathecal methotrexate (12 mg; days 1, 8, and 30) along with daily imatinib (340 mg/m²/once daily) from day 10. Chemotherapy was administered through peripheral intravenous lines on an outpatient basis. Treatment was uneventful up to day 29 of induction when he presented with abdominal pain and fever.

On examination, heart rate was 86/min, blood pressure was 100/70 mm Hg and respiration was 22/min. Abdomen was mildly distended, diffusely tender, and bowel sounds were present. He was started on intravenous fluids, intravenous antibiotics (cefoperazone-sulbactam and amikacin), and analgesics for abdominal pain. The complete blood count showed a hemoglobin of 5 g/dL, platelet of 49 \times 10^9/L, and TLC of 0.42 \times 10^9/L with an absolute neutrophil count of 0.1 \times 10^9/L. Blood tests showed an elevated lipase (1,164 U/L), elevated D-dimer (3,700 ng/mL), with a normal serum sodium (137 mEq/L) and potassium (4.2 mEq/L) and no organism was isolated from blood culture. In view of the above symptoms in a neutropenic child, computerized tomography (CT) scan of the abdomen with contrast was done under the cover of anticoagulation therapy. An incidental finding on CT scan was a well-defined hypodense mass in the left ventricle (LV) of the heart which an imaging findings and elevated D-dimer both strongly suggested a diagnosis of intraventricular thrombus. The child was shifted to the intensive care unit (ICU) where he was continued on analgesics and intravenous antibiotics and kept nil by mouth. He underwent an emergency laparotomy for his abdominal emergency. Intraoperatively, there was a single perforation on the posterior wall of the stomach, and two impending perforations on the proximal jejunal wall, all of which were closed in two layers, using 4-0 polydioxanone suture (►Fig. 1d and e). The surgical procedure was uneventful. Postoperatively, the child continued to be neutropenic (absolute neutrophil count: of 0.1 \times 10^9/L) with a platelet count of 40 \times 10^9/L. He was continued on intravenous antibiotics and was started on the low-molecular weight heparin (LMWH) enoxaparin at 1 mg/kg/dose twice a day for the large cardiac thrombus. Given his postoperative state and neutropenia, it was decided to defer any major cardiac surgery. The day after surgery the child was extubated from the ventilator and started on clear liquids, his pancreatic enzymes had returned to normal. On the subsequent day (postoperative day 2) he developed a sudden cardiac arrest and could not be revived. Permission for autopsy was not obtained.

**Discussion**

Philadelphia chromosome (Ph⁺) ALL comprises only 3%–5% of childhood ALL, the outcomes of which have been dismal until the addition of tyrosine kinase inhibitor, imatinib. While imatinib has been linked to pneumatosis intestinalis in a child with acute leukemia, most clinical trials for childhood Ph⁺ ALL have not reported this as a significant toxicity. Of interest was L-asparaginase, linked to pancreatitis in 6.7%–18% of children being treated for ALL. The clinical course of drug-induced pancreatitis can vary from mild to severe and in our patient serum lipase returned to normal within 72 hours and CT abdomen showed no evidence of pseudocyst or necrosis, excluding severe pancreatitis as a cause of gastrointestinal perforation. Gastrointestinal tract perforation is reportedly seen in less than 1% of patients on induction therapy for ALL. L-asparaginase-related jejunal perforation has been described in a patient with ALL, with the etiology related to the prothrombotic state induced by reducing levels of natural anticoagulants such as protein C, protein S, Antithrombin III, and plasminogen. Also, imatinib has very rarely been reported to cause bowel perforation, but given the rarity and length of exposure it is unlikely to be the causative factor in our patient.

Thrombotic complications are seen in 2%–7% of patients with ALL receiving asparaginase. The driving mechanism for thrombosis is related to the depletion of L-asparaginase-dependent hemostatic protein synthesis. Thrombotic events most often occur during induction and corticosteroids may contribute by inducing synthesis of procoagulants as well as by inducing vascular changes. Majority of patients develop venous thrombosis, but arterial thrombosis has also been reported. Thrombosis secondary to L-asparaginase is usually managed with LMWH. L-asparaginase may need temporary discontinuation in the presence of clinically significant thrombotic events, however, reexposure is considered to be safe and feasible and is usually done under the cover of anticoagulation therapy. Intracardiac thrombus amongst patients receiving L-asparaginase usually involves the right atrium in 2%–14% of children with ALL and is usually related to the presence of catheter tip in right atrium while the LV has not been described as a site for a thrombus. LV thrombosis has been described in patients with hypereosinophilic syndrome, as well as in a child with acquired protein C deficiency. Amongst adults, LV thrombus commonly occurs following myocardial infarction but has also occasionally been described amongst patients with cancer. LV thrombus poses a risk of embolism resulting in ischemic stroke and peripheral embolism, because of which immediate anticoagulation therapy is recommended. In adults the preferred anticoagulation is usually oral warfarin along with low dose aspirin for 3 to 6 months. Surgery is recommended if the general condition of the patient is preserved. Since
our patient was a child who had undergone a major gastric surgery, he was commenced on subcutaneous LMWH and since he was severely neutropenic it was decided to defer any cardiac surgery until the time of count recovery.

Our patient did not have any past history of thrombotic episodes or family history of thrombophilia, but the co-occurrence of these unusual complications made us strongly suspect a underlying prothrombotic condition exacerbated by L-asparaginase therapy. The prevalence of genetic prothrombotic abnormalities amongst children with ALL varies around the world, and we do not pre-emptively screen for thrombophilia given that such testing is expensive, and not easily available. The Dutch Children’s Oncology Group has debated the benefit of more aggressive screening and LMWH
prophylaxis during induction for those found to have thombo-
bophilia. The role of genetic predisposition for pancreatitis
is less clear but recent genome-wide association studies have
found different candidate single-nucleotide polymorphisms
associated with pancreatitis in patients with ALL. We
could not rule out a pre-existing cardiac thrombus as a baseline
2D-echo was unavailable. Also, thrombotic events and gas-
tric perforation during ALL therapy are often considered to
be multifactorial rather than secondary to a single drug. But,
the occurrence of several unique toxicities which are often
shown to be associated with L-asparaginase, all occurring
simultaneously in a patient would be the highlight of this
case report.

Conclusion

Though L-asparaginase is an essential drug for the manage-
ment of childhood ALL, it does possess a unique toxicity
profile. Unfortunately, our patient simultaneously experi-
enced several toxicities, including pancreatitis, LV thrombus,
and gastrointestinal perforation leading to his demise. Lack
of familiarity of the toxicity profile of this drug can make L-
asparaginase a difficult drug to use. Being vigilant for these
unusual toxicities especially during induction chemotherapy
is essential for optimal patient care.

Source of Support
None.

Declaration of Patient Consent

The authors certify that they have obtained all appropri-
ate patient consent forms.

Conflict of interest

None declared.

References

1 Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for
children with acute lymphoblastic leukemia: results of Dana-
tinuation on outcome in childhood acute lymphoblastic leukae-
ia: a report from the Children’s Oncology Group. J Clin Oncol
2020;38(17):1897–1905
3 Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in
children with acute lymphoblastic leukemia. Leuk Lymphoma
2016;57(04):748–757
survival with imatinib in Philadelphia chromosome-positive acute
2009;27(31):5175–5181
5 Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction
for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL):
a randomised, open-label, intergroup study. Lancet Oncol 2012;
13(09):936–945
6 O’Rafferty C, McElligott F, Storey L, O’Marcaigh A, Smith O.
Pneumatosis intestinalis and imatinib mesylate. Ann Hematol
2014;93(10):1783–1784
7 Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated
8 Wolthers BO, Frandsen TL, Baruchel A, et al; Ponte di Legno
Toxicity Working Group. Asparaginase-associated pancreatitis in
childhood acute lymphoblastic leukaemia: an observational
Ponte di Legno Toxicity Working Group study. Lancet Oncol 2017;
18(09):1238–1248
9 Mörcke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone
vs prednisone in induction treatment of pediatric ALL: results of
the randomized trial AIEOP-BFM ALL 2000. Blood 2016;127(17):
2101–2112
10 Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-
Asparaginase and the effect of age on coagulation and fibrinolysis
in childhood acute lymphoblastic leukemia. Thromb Haemost
2008;100(02):330–337
11 Tang ER, Chapman T, Finn LS, Leger KJ. Perforated jejunitis in a
child with acute lymphoblastic leukemia treated with pegasparg-
ase. Radiol Case Rep 2018;13(03):568–572
12 El Jurdi N, Bankoff M, Klein A, Saif MW. Perforation of the colon
during imatinib mesylate (Gleevec) treatment in a patient with
chronic myeloid leukemia (CML). Cureus 2016;8(06):e660
13 Tadaiya MV, Tankshali RA. Multiple small bowel perforations in a
patient of chronic myeloid leukemia on imatinib. Indian J Med
Paediatr Oncol 2020;41:89–92
14 Chiarugi M, Galatiero C, Lippolis PV, Seccia M. Multiple bowel
perforations complicating imatinib treatment for advanced gas-
386–387
15 Riley DO, Schleifman JM, Vitzthum Von Eckaestad V HC, Morris AL,
Keng MK, El Chaer F. Pegaspargase in practice: minimizing
toxicity, maximizing benefit. Curr Hematol Malig Rep 2021;16
(03):314–324
16 Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukae-
17 Athale UH, Chan AK. Thrombosis in children with acute lympho-
blastic leukemia: part I. Epidemiology of thrombosis in children
125–131
18 Mitchell LG, Andrew M, Hanna K, et al; Prophylactic Antithrombin
Replacement in Kids with Acute Lymphoblastic Leukemia Treated
with Asparaginase Group (PARKAA) A prospective cohort study
determining the prevalence of thrombotic events in children with
acute lymphoblastic leukemia and a central venous line who are
treated with L-asparaginase: results of the Prophylactic Anti-
thrombin Replacement in Kids with Acute Lymphoblastic Leuk-
eaemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97
(02):508–516
19 Atalay S, Akar N, Tutar HE, Yilmaz E. Factor V 1691 G-A mutation
Paediatr 2002;91(02):168–171
20 Williams E, Smart SC, Go RS. Catastrophic thromboembolism in a
patient with acute lymphoblastic leukemia and hypereosino-
philia. Haematologica 2004;89(04):E101
21 McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi JL Jr, Bhatt
DL, McEvoy JW. Left ventricular thrombus after acute myocardial
infarction: screening, prevention, and treatment. JAMA Cardiol
2018;3(07):642–649
22 Oeser C, Andreas M, Rath C, Haberthuer A, Kocher A. Left
ventricular thrombus in a patient with cutaneous T-cell lympho-
0ma, hypereosinophilia and Mycoplasma pneumoniae infection—a
10:21
ventricular thrombus associated with platinum-based chemo-
therapy plus cetuximab for the treatment of metastatic squamous
cell carcinoma of the head and neck: a case report. Mol Clin Oncol
2017;7(05):833–836